Research location

Targovishte

Bulgaria

Published trials31

Site observations31

Linked trials published31

Page1 / 1

Research activity in Targovishte

Bulgaria

CureCurrent currently publishes aggregate city-level research activity for this location: 31 trials and 31 site observations.

The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.

Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.

Trials with sites in Targovishte

31 linked trials · page 1 of 1

Evaluation of NBI-1117570 in Inpatient Adults With SchizophreniaNCT07288333 · 2026-02-16 · 1 site observation

Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive DisorderNCT06830044 · 2025-03-03 · 1 site observation

Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With SchizophreniaNCT03817502 · 2019-06-06 · 1 site observation

Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive DisorderNCT06058039 · 2023-12-21 · 1 site observation

Emp-Activity: Empagliflozin Functional CapacityNCT05350202 · 2022-12-18 · 1 site observation

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaNCT05304767 · 2022-03-07 · 1 site observation

A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of SchizophreniaNCT05145413 · 2021-11-12 · 1 site observation

An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderNCT05061719 · 2021-10-08 · 1 site observation

Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive DisorderNCT05061706 · 2021-09-30 · 1 site observation

Lumateperone for the Prevention of Relapse in Patients With SchizophreniaNCT04959032 · 2021-07-08 · 1 site observation

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With SeltorexantNCT04533529 · 2020-09-16 · 1 site observation

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants AloneNCT03738215 · 2018-11-09 · 1 site observation

Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With SchizophreniaNCT03593213 · 2018-07-30 · 1 site observation

Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of SchizophreniaNCT03397134 · 2017-12-15 · 1 site observation

Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted GloballyNCT03249376 · 2017-11-27 · 1 site observation

A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant TherapyNCT03227224 · 2017-08-16 · 1 site observation

Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant SchizophreniaNCT03230864 · 2017-07-20 · 1 site observation

Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of AgeNCT03108625 · 2017-03-01 · 1 site observation

Extension Study of Pimavanserin for the Adjunctive Treatment of SchizophreniaNCT03121586 · 2017-01-01 · 1 site observation

Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)NCT02970305 · 2016-11-04 · 1 site observation

Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)NCT02970292 · 2016-10-26 · 1 site observation

Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of AgeNCT02871297 · 2016-08-17 · 1 site observation

Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)NCT02709746 · 2016-05-01 · 1 site observation

Pediatric Open-Label Extension StudyNCT01914393 · 2013-09-30 · 1 site observation

Pediatric Schizophrenia Efficacy and Safety StudyNCT01911429 · 2013-08-01 · 1 site observation

An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)NCT01895452 · 2013-07-01 · 1 site observation

A Study of Usage of Paliperidone Palmitate in Patients With Schizophrenia in a Hospital SettingNCT01926912 · 2013-05-01 · 1 site observation

A Double-Blind Study Evaluating Duvelisib in Subjects With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate AloneNCT01851707 · 2013-04-01 · 1 site observation

A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)NCT01626456 · 2012-06-01 · 1 site observation

A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With SchizophreniaNCT01469039 · 2011-12-01 · 1 site observation

Safety and Tolerability of Aripiprazole in Adolescents With Schizophrenia or Children and Adolescents With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features.NCT01122927 · 2010-07-01 · 1 site observation

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.